In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

Launched by HEATHER WACHTEL · Dec 1, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a special type of imaging called 18F-FluorThanatrace PET/CT to see how a protein called PARP-1 behaves in patients with pheochromocytoma or paraganglioma, which are types of tumors that can affect the adrenal glands and other areas of the body. The study will involve up to 30 patients who are 18 years or older and have been diagnosed with these tumors. Before they receive any treatment, participants will undergo a PET/CT scan to observe PARP-1 expression in their tumors. It's important to note that while the results of this scan will be shared with the patients and their doctors, they will not be used to decide on treatment options.

To take part in this study, patients must have a confirmed diagnosis of pheochromocytoma or paraganglioma, and they should be willing to provide informed consent. This means they understand the study's purpose and agree to participate. Participants should be in good enough health to undergo the imaging procedures, and women who are pregnant or breastfeeding cannot join. This study is currently recruiting, and it aims to enhance our understanding of these tumors, which could help improve future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participants will be ≥ 18 years of age.
• • 2. Clinical diagnosis of pheochromocytoma or paraganglioma based on biochemical and imaging studies At least one lesion identified on standard of care imaging (e.g. CT, MRI, FDG or 68-Gallium dotatate, other PET/CT or MIBG).
• • 3. Standard of care germline genetic testing performed for clinical purposes or participant's consent for germline genetic testing for research purposes.
• • 4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
• Exclusion Criteria:
• • 1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
• • 2. Females who are pregnant or breastfeeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to FTT injection.
• • 3. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.